Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.cipla.com | |
Market Cap | 83,244.79 Cr. | |
Enterprise Value(EV) | 82,262.92 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 32.69 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 31.56 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.80 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 281.14 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 3.67 | Calculated using Price: 1,031.50 |
Dividend Yield | 0.48 | Period Ending 2022-03 |
No. of Shares Subscribed | 80.71 Cr. | 807,143,930 Shares |
FaceValue | 2 | |
Company Profile | ||
The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets. |
1 Day |
|
+0.17% |
1 Week |
|
+1.43% |
1 Month |
|
-4.18% |
3 Month |
|
-8.81% |
6 Month |
|
-0.27% |
1 Year |
|
+10.49% |
2 Year |
|
+21.70% |
5 Year |
|
+81.24% |
10 Year |
|
+161.77% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 14.89 | 12.10 | 12.61 | 8.72 | 10.65 | 10.37 | 10.09 | 14.13 | 13.10 | |
Return on Capital Employed (%) | 19.05 | 15.33 | 13.24 | 8.28 | 10.20 | 11.94 | 12.53 | 17.85 | 17.24 | |
Return on Assets (%) | 10.49 | 7.85 | 7.28 | 4.97 | 6.52 | 6.50 | 6.56 | 9.95 | 9.94 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 10,050 | 10,801 | 11,516 | 12,544 | 14,229 | 15,012 | 15,763 | 18,327 | 20,842 | 21,884 | |
Non Curr. Liab. | 2,028 | 2,418 | 1,407 | 4,513 | 4,259 | 4,646 | 2,972 | 1,660 | 622 | 117 | |
Curr. Liab. | 2,564 | 3,881 | 7,776 | 3,374 | 3,832 | 3,772 | 4,393 | 4,591 | 4,913 | 5,309 | |
Minority Int. | 50 | 180 | 350 | 438 | 352 | 332 | 294 | 259 | 276 | 285 | |
Equity & Liab. | 14,692 | 17,281 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 27,596 | |
Non Curr. Assets | 9,040 | 9,689 | 12,208 | 12,064 | 11,859 | 11,335 | 11,717 | 11,628 | 11,925 | 11,690 | |
Curr. Assets | 5,652 | 7,591 | 8,841 | 8,736 | 10,814 | 12,425 | 11,704 | 13,181 | 14,711 | 15,906 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 14,692 | 17,281 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 27,596 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 10,173 | 11,345 | 13,595 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,274 | |
Other Income | 265 | 166 | 208 | 229 | 358 | 477 | 369 | 270 | 322 | 405 | |
Total Income | 10,439 | 11,511 | 13,803 | 14,623 | 15,513 | 16,839 | 17,501 | 19,429 | 22,085 | 22,679 | |
Total Expenditure | -8,040 | -9,184 | -11,115 | -11,919 | -12,329 | -13,265 | -13,951 | -14,911 | -17,251 | -17,671 | |
PBIDT | 2,398 | 2,327 | 2,688 | 2,704 | 3,184 | 3,574 | 3,550 | 4,518 | 4,834 | 5,008 | |
Interest | -146 | -168 | -207 | -159 | -114 | -168 | -197 | -161 | -106 | -93 | |
Depreciation | -373 | -505 | -754 | -1,323 | -1,323 | -1,326 | -1,175 | -1,068 | -1,052 | -1,116 | |
Taxation | -463 | -400 | -332 | -180 | -250 | -570 | -631 | -889 | -934 | -1,052 | |
Exceptional Items | -78 | -182 | -58 | ||||||||
PAT | 1,417 | 1,254 | 1,395 | 1,042 | 1,419 | 1,510 | 1,547 | 2,401 | 2,559 | 2,689 | |
Minority Interest | -16 | -48 | -23 | -29 | -6 | 35 | 47 | 16 | -30 | -44 | |
Share Associate | -12 | -25 | -12 | -7 | -3 | -17 | -47 | -13 | -13 | -7 | |
Other Related Items | |||||||||||
Consolidated Net Profit | 1,388 | 1,181 | 1,360 | 1,006 | 1,411 | 1,528 | 1,547 | 2,405 | 2,517 | 2,638 | |
Adjusted EPS | 17 | 15 | 17 | 13 | 18 | 19 | 19 | 30 | 31 | 33 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 1,398 | 1,563 | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | |
Cash Fr. Inv. | -2,063 | -1,250 | -941 | -4,523 | -1,310 | -854 | -1,669 | 104 | -2,387 | -1,872 | |
Cash Fr. Finan. | 718 | -266 | 165 | 3,104 | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | |
Net Change | 53 | 48 | 397 | 322 | -254 | 223 | -326 | 224 | 129 | -146 | |
Cash & Cash Eqvt | 143 | 176 | 564 | 858 | 610 | 853 | 508 | 742 | 790 | 658 |
Mon, 06 Feb 2023
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 We hereby notify that the Income Tax Department (the Department) conducted a search under the Income Tax Act 1961 at some of our offices and manufacturing units. The Company fully co-operated with the officials during the proceedings and responded to the clarifications and details sought by them. We will continue to provide any further clarification /information that may be required.The business operations of the Company continued as usual and were not impacted due to the search.We will comply with our legal obligation for disclosure from time to time. |
Mon, 30 Jan 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript We are enclosing herewith copy of the transcript of the Companys Q3 FY23 earnings conference call dated 25th January 2023. The transcript is also available on the Companys website i.e. https://www.cipla.com/sites/default/files/Earnings-Call-Transcript-Q3FY23.pdf . |
Wed, 25 Jan 2023
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31St December 2022 The Board of Directors of the Company at its meeting held today i.e. 25th January 2023 has inter-alia approved the unaudited financial results (standalone and consolidated) for the quarter and nine months ended 31st December 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed as follows: (1) Unaudited financial results (standalone and consolidated) as per Indian Accounting Standards for the quarter and nine months ended 31st December 2022; and (2) Limited review report (standalone and consolidated) by Walker Chandiok & Co LLP Statutory Auditor of the Company for the quarter and nine months ended 31st December 2022. The meeting of the Board of Directors of the Company commenced at 10.30 a.m. (IST) and is still in progress. |
Tue, 07 Feb 2023 |
|
|
|
|
Mon, 06 Feb 2023 |
|